LEXARIA BIOSCIENCE CORP. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
LEXARIA BIOSCIENCE CORP. (LEXX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $92.94 thousand for the 3-month period ending 2026-05-31, per its 10-Q filed 2026-07-13.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-07-13
- LEXARIA BIOSCIENCE CORP. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-05-31 was $92.94K, a 80.23% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-02-28 was $74.89K.
- LEXARIA BIOSCIENCE CORP. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-11-30 was $74.89K, a 24.66% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-05-31 was $470.14K, a 37.56% increase year-over-year.
- LEXARIA BIOSCIENCE CORP. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $635.49K, a 29.10% increase from fiscal 2024.
- LEXARIA BIOSCIENCE CORP. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $492.24K.
- LEXARIA BIOSCIENCE CORP. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- LEXARIA BIOSCIENCE CORP. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $278.11K, a 32.17% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 1 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-05-31 | $92.94K 10-Q · filed 2026-07-13 | $167.84K derived: sum of 2 quarters · filed 2026-07-13 | $242.73K derived: sum of 3 quarters · filed 2026-07-13 | ||
| 2026-02-28 | $74.89K 10-Q · filed 2026-07-13 | $149.79K derived: sum of 2 quarters · filed 2026-07-13 | |||
| 2025-11-30 | $74.89K 10-Q · filed 2026-07-13 | ||||
| 2025-08-31 | $635.49K 10-K · filed 2025-11-28 | ||||
| 2025-05-31 | $470.14K 10-Q · filed 2026-07-13 | ||||
| 2024-11-30 | $99.42K 10-Q · filed 2026-07-13 | ||||
| 2024-08-31 | $492.24K 10-K · filed 2025-11-28 | ||||
| 2024-05-31 | $341.77K 10-Q · filed 2025-07-14 | ||||
| 2023-11-30 | $53.95K 10-Q · filed 2025-07-14 | ||||
| 2023-08-31 | $0.00 10-K · filed 2023-11-20 | ||||
| 2022-08-31 | $278.11K 10-K · filed 2023-11-20 | ||||
| 2022-05-31 | $111.17K 10-Q · filed 2022-07-14 | ||||
| 2021-11-30 | $408.54K 10-Q · filed 2022-04-11 | $408.54K derived: sum of 2 quarters · filed 2022-04-11 | $752.51K derived: sum of 3 quarters · filed 2022-07-14 | $769.66K derived: sum of 4 quarters · filed 2022-07-14 | |
| 2021-09-30 | $408.54K 10-Q · filed 2022-07-14 | ||||
| 2021-08-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-29 | $343.97K derived: sum of 2 quarters · filed 2022-07-14 | $361.12K derived: sum of 3 quarters · filed 2022-07-14 | $410.01K 10-K · filed 2021-11-29 | |
| 2021-05-31 | $343.97K 10-Q · filed 2022-07-14 | $361.12K derived: sum of 2 quarters · filed 2022-07-14 | $410.01K 10-Q · filed 2021-07-15 | $410.01K derived: sum of 4 quarters · filed 2022-07-14 | |
| 2021-02-28 | $17.15K 10-Q · filed 2022-07-14 | $66.04K derived: sum of 2 quarters · filed 2022-07-14 | $66.04K derived: sum of 3 quarters · filed 2022-07-14 | $748.60K derived: sum of 4 quarters · filed 2022-07-14 | |
| 2020-11-30 | $48.89K 10-Q · filed 2022-07-14 | $48.89K derived: sum of 2 quarters · filed 2022-07-14 | $731.45K derived: sum of 3 quarters · filed 2022-07-14 | $1.03M derived: sum of 4 quarters · filed 2022-07-14 | |
| 2020-08-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-29 | $682.56K derived: sum of 2 quarters · filed 2021-11-29 | $976.86K derived: sum of 3 quarters · filed 2021-11-29 | $1.14M 10-K · filed 2021-11-29 | |
| 2020-05-31 | $682.56K 10-Q · filed 2021-04-14 | $976.86K derived: sum of 2 quarters · filed 2021-04-14 | $1.14M 10-Q · filed 2021-07-15 | $1.26M derived: sum of 4 quarters · filed 2021-04-14 | |
| 2020-02-29 | $294.29K 10-Q · filed 2021-04-14 | $456.71K derived: sum of 2 quarters · filed 2021-04-14 | $576.09K derived: sum of 3 quarters · filed 2021-04-14 | $1.02M derived: sum of 4 quarters · filed 2021-04-14 | |
| 2019-11-30 | $162.41K 10-Q · filed 2021-04-14 | $281.80K derived: sum of 2 quarters · filed 2021-04-14 | $725.06K derived: sum of 3 quarters · filed 2021-04-14 | ||
| 2019-08-31 | $119.38K 10-Q · filed 2020-06-29 | $562.65K derived: sum of 2 quarters · filed 2020-06-29 | $626.69K 10-K · filed 2020-10-15 | ||
| 2019-05-31 | $443.27K 10-Q · filed 2020-06-29 | ||||
| 2018-11-30 | $64.04K 10-Q · filed 2020-06-29 | $563.58K derived: sum of 2 quarters · filed 2020-06-29 | $2.54M derived: sum of 3 quarters · filed 2020-06-29 | $2.67M derived: sum of 4 quarters · filed 2020-06-29 | |
| 2018-08-31 | $499.54K 10-Q · filed 2019-07-08 | $2.48M derived: sum of 2 quarters · filed 2019-07-08 | $2.60M derived: sum of 3 quarters · filed 2019-07-08 | $2.60M 10-Q · filed 2020-01-09 | |
| 2018-05-31 | $1.98M 10-Q · filed 2019-07-08 | $2.10M derived: sum of 2 quarters · filed 2019-07-08 | $2.10M 10-Q · filed 2018-07-13 | ||
| 2018-02-28 | $122.56K 10-Q · filed 2019-07-08 | $122.56K 10-Q · filed 2018-04-12 | |||
| 2017-08-31 | $76.40K derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-14 | $76.40K derived: sum of 2 quarters · filed 2018-11-14 | $76.40K derived: sum of 3 quarters · filed 2018-11-14 | $93.97K 10-K · filed 2018-11-14 | |
| 2017-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-07-14 | $0.00 derived: sum of 2 quarters · filed 2017-07-14 | $17.57K 10-Q · filed 2017-07-14 | $49.79K derived: sum of 4 quarters · filed 2018-11-14 | |
| 2017-02-28 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-04-14 | $17.57K 10-Q · filed 2017-04-14 | $49.79K derived: sum of 3 quarters · filed 2018-11-14 | ||
| 2016-11-30 | $17.57K 10-Q · filed 2017-01-13 | $49.79K derived: sum of 2 quarters · filed 2018-11-14 | |||
| 2016-08-31 | $32.22K derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-14 | $83.86K 10-K · filed 2018-11-14 | |||
| 2016-05-31 | $51.64K 10-Q · filed 2016-07-13 | ||||
| 2015-08-31 | $197.00K 10-K · filed 2016-11-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |